---
title: "Sipai Health Technology Co., Ltd. (00314.HK)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/00314.HK.md"
symbol: "00314.HK"
name: "Sipai Health Technology Co., Ltd."
industry: "Drug Retail"
---

# Sipai Health Technology Co., Ltd. (00314.HK)

| Item | Detail |
|------|--------|
| Industry | Drug Retail |
| Location | HK Market |
| Website | [www.medbankshealthtech.com](https://www.medbankshealthtech.com) |

## Company Profile

Sipai Health Technology Co., Ltd. operates as a medical technology and health management company in the People’s Republic of China. The company operates through three segments: Specialty Pharmacy Business, Physician Research Assistance Business, and Health Insurance Services Business. The Specialty ...

## Financial Score

> *Longbridge Financial Score™ — Proprietary multi-factor rating model by [Longbridge](https://longbridge.com). This score is independently calculated by Longbridge and is not affiliated with any third-party rating agency.*
> Updated: 2026-02-14T04:30:10.000Z

**Overall: D (0.63)**

**Industry**: Drug Retail

| Metric | Value |
|--------|-------|
| Industry Ranking | 7 / 7 |
| Industry Median | B |
| Industry Average | B |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Small - The company's operation has a high degree of growth and volatility, making it easy to achieve high investment returns.

### Score Analysis

**Style Score**: 

#### Growth Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -26.03% |  |
| Net Profit YoY | -31.60% |  |

#### Value Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| P/B Ratio | 1.51 |  |
| Dividend Ratio | 0.00% |  |


**Size Score**: 

#### Market Cap Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 1.65B |  |

#### Revenue Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue | 3.71B |  |


**Multi Score**: D

#### Profit Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | -25.48% | E |
| Profit Margin | -9.27% | D |
| Gross Margin | 14.39% | D |

#### Growth Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | -26.03% | E |
| Net Profit YoY | -31.60% | D |
| Total Assets YoY | -36.01% | E |
| Net Assets YoY | -35.57% | E |

#### Cash Score: E

| Indicator | Value | Rating |
|-----------|-------|--------|
| Cash Flow Margin | -1078.90% | E |
| OCF YoY | -26.03% | E |

#### Operating Score: A

| Indicator | Value | Rating |
|-----------|-------|--------|
| Turnover | 1.44 | A |

#### Debt Score: C

| Indicator | Value | Rating |
|-----------|-------|--------|
| Gearing Ratio | 47.81% | C |


```chart-data:radar
{
  "title": "Longbridge Financial Score - Sipai Health Technology Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Profit",
      "grade": "E",
      "indicators": [
        {
          "name": "ROE",
          "value": "-25.48%",
          "rating": "E"
        },
        {
          "name": "Profit Margin",
          "value": "-9.27%",
          "rating": "D"
        },
        {
          "name": "Gross Margin",
          "value": "14.39%",
          "rating": "D"
        }
      ]
    },
    {
      "name": "Growth",
      "grade": "E",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "-26.03%",
          "rating": "E"
        },
        {
          "name": "Net Profit YoY",
          "value": "-31.60%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "-36.01%",
          "rating": "E"
        },
        {
          "name": "Net Assets YoY",
          "value": "-35.57%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Cash",
      "grade": "E",
      "indicators": [
        {
          "name": "Cash Flow Margin",
          "value": "-1078.90%",
          "rating": "E"
        },
        {
          "name": "OCF YoY",
          "value": "-26.03%",
          "rating": "E"
        }
      ]
    },
    {
      "name": "Operating",
      "grade": "A",
      "indicators": [
        {
          "name": "Turnover",
          "value": "1.44",
          "rating": "A"
        }
      ]
    },
    {
      "name": "Security",
      "grade": "C",
      "indicators": [
        {
          "name": "Gearing Ratio",
          "value": "47.81%",
          "rating": "C"
        }
      ]
    }
  ]
}
```

### Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
|------|------|--------|--------|-----------|----------|------|--------|
| 01 | JD HEALTH (HK.6618) | B | B | B | B | B | B |
| 02 | JD HEALTH-R (HK.86618) | B | B | B | B | B | B |
| 03 | ALI HEALTH (HK.241) | B | B | A | B | B | B |
| 04 | PA GOODDOCTOR (HK.1833) | C | B | C | B | A | B |
| 05 | FANGZHOU JIANKE (HK.6086) | D | A | A | E | D | C |

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -4.73 | 6/7 | - | - | - |
| PB | 1.51 | 2/7 | 2.99 | 2.35 | 1.71 |
| PS (TTM) | 0.44 | 2/7 | 0.81 | 0.65 | 0.50 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2025-07-16T16:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.23 |
| Highest Target | 9.20 |
| Lowest Target | 9.20 |

## References

- [Company Overview](https://longbridge.com/en/quote/00314.HK/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/00314.HK/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/00314.HK/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.